Crohn's & colitis 360
Cure8 research brief
Why This Matters
The study identifies a sizable group of patients in Latin America with difficult-to-treat IBD—especially Crohn’s disease—highlighting higher disease severity, younger onset, and longer diagnostic delays that can affect care needs and planning.
Who Should Pay Attention
Adult IBD patients (especially those with Crohn's and perianal disease), gastroenterologists and IBD specialists in Latin America, healthcare planners, and researchers studying IBD severity and outcomes.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study used retrospective registry data from multiple Latin American sources to compare patients who met DTT-IBD criteria versus those who did not. DTT-IBD patients were younger at symptom onset and diagnosis and experienced longer diagnostic delays.
Among DTT-CD patients, complex perianal disease and penetrating behavior were common; among DTT-UC patients, extensive colitis and failure of multiple advanced therapies were prominent.
Care implications These findings suggest a substantial subgroup of patients in LATAM have severe, treatment-refractory disease and may need multidisciplinary care, earlier specialist referral, and strategies to reduce diagnostic delay. Health systems and clinicians in the region may need to plan resources accordingly.
Keep In Mind
This is a retrospective registry study using international consensus criteria for DTT-IBD and aggregated data from multiple LATAM registries. As an observational study, it describes prevalence and associations but does not establish causation. The structured content depth is an abstract of the published article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCrohn's & colitis 360
AuthorsYamamoto-Furusho JK, Fróes R, Flores C +11 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJun 13, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
What Even Is ‘Moderate’ IBD? Experts Can’t Agree
How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might...
Risk of Inflammatory Bowel Disease Following Hospital-Treated Infections and Modulatory Role of Host Genetics to Support a Multi-Hit Pathogenesis Model.
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
‘Getting closer’: Genetic risk scores may help predict inflammatory bowel disease severity
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...